Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7bb8b95d7b-dtkg6 Total loading time: 0 Render date: 2024-09-12T03:31:53.646Z Has data issue: false hasContentIssue false

Oncology and Hematology Medications

from Section 2 - Medication Adverse Effects

Published online by Cambridge University Press:  30 May 2019

By
Latha Radhakrishnan  and
Scott M. Wirth
Edited by
Alan B. Ettinger ,
Deborah M. Weisbrot  and
Casey E. Gallimore
Alan B. Ettinger
Affiliation:
Safe Passage Diagnostics, New York
Deborah M. Weisbrot
Affiliation:
State University of New York, Stony Brook
Casey E. Gallimore
Affiliation:
University of Wisconsin
Get access
Type
Chapter
Information
Synopsis of Neurology, Psychiatry and Related Systemic Disorders , pp. 754 - 763
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Blincyto® (blinatumomab) package insert. Thousand Oaks, CA: Amgen Inc.; 2014.Google Scholar
Topp, MS, Gökbuget, N, Zugmaier, G et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32: 4134.Google Scholar
Topp, MS, Gökbuget, N, Stein, AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16: 57–66.Google Scholar
Cytarabine injection package insert. Rockford, IL: Mylan Institutional LLC; 2014.Google Scholar
Herzig, RH, Hines, JD, Herzig, GP, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987; 5: 927–32.Google Scholar
Jolson, HM, Bosco, L, Bufton, MG, et al. Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine. J Natl Cancer Inst. 1992; 84: 500.Google Scholar
Smith, GA, Damon, LE, Rugo, HS, Ries, CA, Linker, CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997; 15: 833.CrossRefGoogle ScholarPubMed
Darbepoetin alfa. In Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. http://online.lexi.com. Accessed Jun 28, 2016.Google Scholar
Epoetin alfa. In Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. http://online.lexi.com. Accessed Jun 28, 2016.Google Scholar
Hematopoietic agents. In AHFS Drug Information STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. http://online.statref.com/document.aspx?fxid=1&docid=497. Accessed Jun 28, 2016.Google Scholar
Pirzada, NA, Imram, IA, Dafer, RM. Fluorouracil induced neurotoxicity. Ann Pharmacother. 2000; 34: 35–8.Google Scholar
Renoir, D, Gill, S. Capecitabine-induced cerebellar toxicity. Clin Colorectal Cancer. 2006; 6: 70.Google Scholar
Said, MW, Wood, TE, McGee, PJ, et al. Peripheral neuropathy associated with capecitabine. Anti-Cancer Drugs. 2004; 15: 767–71.Google Scholar
Videnovic, A, Semenov, I, Chua-Adajar, R, et al. Capecitabine-induced multifocal leukoencephalopthy: a report of five cases. Neurology. 2005; 65: 1792.Google Scholar
Yeh, KH, Cheng, AL. High-dose 5-fluorouracil infusional therapy is associated with hyperammonemia, lactic acidosis and encephalopathy. Br J Cancer. 1997; 75: 464–5.Google Scholar
Filgrastim. In Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. http://online.lexi.com. Accessed Jun 28, 2016.Google Scholar
Hematopoietic Agents. In AHFS Drug Information STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. http://online.statref.com/document.aspx?fxid=1&docid=497. Accessed Jun 28, 2016.Google Scholar
Pegfilgrastim. In Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. http://online.lexi.com. Accessed Jun 28, 2016.Google Scholar
Sargramostim. In Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. http://online.lexi.com. Accessed Jun 28, 2016.Google Scholar
Intron® A (interferon alpha-2b injection, solution) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; Feb 2016.Google Scholar
Kirkwood, JM, Bender, C, Agarwala, S. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002; 20: 3703–18.Google Scholar
Sylatron® (peginterferon alpha-2b injection, powder, lyophilized, for solution) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; Feb 2016.Google Scholar
Cytarabine injection package insert. Rockford, IL: Mylan Institutional LLC; Sep 2014.Google Scholar
DepoCyt® (cytarabine injection, lipid complex) package insert. Gaithersburg, MD: Sigma-Tau Pharmaceuticals, Inc.; Dec 2014.Google Scholar
Dunton, SF, Nitschke, R, Spruce, WE, et al. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study. Cancer. 1986; 57: 1083.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
Methotrexate sodium injection, solution package insert. Rockford IL: Mylan Institutional LLC; Sep 2014.Google Scholar
Bhatia, S, Huber, BR, Upton, MP, et al. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: A case report. J Immunother. 2009; 32: 203–5.CrossRefGoogle ScholarPubMed
Wilgenhof, S, Neyns, B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol. 2011; 22: 991–3Google Scholar
Yervoy® (ipilimumab injection) package insert. Princeton, NJ: E.R. Squibb & Sons, LLC; Mar 2017.Google Scholar
Durando, X, Dalenc, F, Abrial, C, et al. Neurotoxicity as a prognostic factor in patients with metastatic breast cancer treated with ixabepilone as a first-line therapy. Oncology. 2015; 88: 180–8.Google Scholar
Kushlaf, HA. Emerging toxic neuropathies and myopathies. Neurol Clin. 2011; 29: 679–87.Google Scholar
Vahdat, LT, Roche, HH, Hortobagyi, GN, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012; 20: 2661–8.Google Scholar
Arranon® (nelarabine injection) package insert. Research Triangle Park, NC: GlaxoSmithKline LLC; Dec 2014.Google Scholar
Cooper, TM. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag. 2007; 3: 1135–41.Google Scholar
DeAngelo, DJ, Yu, D, Johnson, JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007; 109: 5136.Google Scholar
BiCNU® (carmustine) package insert. Eatontown, NJ: Heritage Pharmaceuticals Inc.; Mar 2017.Google Scholar
Burger, PC, Kamenar, E, Schold, SC, et al. Encephalomyelopathy following high-dose BCNU therapy. Cancer. 1980; 48: 1318.Google Scholar
Gleostine® (lomustine, capsule gel coated) package insert. Miami, FL: NextSource Biotechnology, LLC; Jan 2016.Google Scholar
Gliadel® (carmustine wafer) package insert. Atlanta, GA: Arbor Pharmaceuticals, LLC; Nov 2014.Google Scholar
Mahaley, MS Jr, Whaley, RA, Blue, M, Bertsch, L. Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas. J Neurooncol. 1986; 3: 297–314.Google Scholar
Fleming, RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997; 17: 146S–54S.Google Scholar
Ifosfamide injection, solution package insert. Deerfield IL: Baxter Healthcare Corporation; Aug 2014.Google Scholar
Klastersky, J. Side effects of ifosfamide. Oncology. 2003; 65(Suppl 2): 7–10.CrossRefGoogle ScholarPubMed
Patel, PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother. 2006; 40: 299–303.Google Scholar
Amptoulach, S, Tsavaris, N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract. 2011; 2011: 843019.Google Scholar
Avan, A, Postma, TJ, Ceresa, C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015; 20: 411–32.Google Scholar
Miltenburg, NC, Boogerd, W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014; 40: 872–82.Google Scholar
Kyprolis® (carfilzomib injection, powder, lyophilized, for solution) package insert. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc.; May 2017.Google Scholar
Moreau, P, Pylypenko, H, Grosicki, S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12: 431.CrossRefGoogle ScholarPubMed
Ninlaro® (ixazomib citrate capsule) package insert. Cambridge, MA: Millennium Pharmaceuticals, Inc.; Nov 2015.Google Scholar
Velcade® (bortezomib injection, powder, lyophilized, for solution) package insert. Cambridge, MA: Millennium Pharmaceuticals, Inc.; Sep 2015.Google Scholar
Vij, R, Wang, M, Kaufman, JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012; 119: 5661.Google Scholar
Bourque, A, Karama, S, Looper, K, et al. Acute tamoxifen-induced depression and its prevention with venlafaxine. Psychosomatics. 2009; 50: 162–5.Google Scholar
Thompson, DS, Spanier, CA, Vogel, VG. The relationship between tamoxifen, estrogen, and depressive symptoms. Breast J. 1999; 5: 375–82.Google Scholar
Yang, ZD, Yu, J, Zhang, Q. Effects of raloxifene on cognition, mental health, sleep, and sexual function in menopausal women. Maturitas. 2013; 75: 341–8.Google Scholar
Abraxane® (paclitaxel injection, powder, lyophilized, for suspension) package insert. Summit, NJ: Abraxis BioScience, LLC; Jul 2015.Google Scholar
Gorenstein, E, Schwarz, TL. The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions. Neuropharmacology. 2014; 76: 175–83.Google Scholar
Jevtana® (cabazitaxel injection, solution) package insert. Bridgewater, NJ: Sanofi-aventis US LLC; May 2017.Google Scholar
Kudlowitz, D, Muggia, F. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Expert Opin Drug Metab Toxicol. 2014; 13: 681–5.Google Scholar
Dimopoulos, MA, Chen, C, Spencer, A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009; 23: 2147.Google Scholar
Pomalyst® (pomalidomide capsule) package insert. Summit, NJ: Celgene Corporation; Jun 2016.Google Scholar
Revlimid® (lenalidomide capsule) package insert. Summit, NJ: Celgene Corporation; Jan 2017.Google Scholar
San Miguel, J, Weisel, K, Moreau, P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14: 1055.Google Scholar
Thalomid® (thalidomide capsule) package insert. Summit, NJ: Celgene Corporation; Jan 2017.Google Scholar
Cyramza® (ramucirumab solution) package insert. Indianapolis, IN: Eli Lilly and Company; Mar 2017.Google Scholar
Avastin® (bevacizumab injection, solution) package insert. South San Francisco, CA: Genentech, Inc.; Dec 2016.Google Scholar
Ozcan, C, Wong, SJ, Hari, P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006; 354: 980–2.Google ScholarPubMed
Zaltrap® (ziv-aflibercept solution) package insert. Bridgewater, NJ: Sanofi-aventis US LLC; Jun 2016.Google Scholar
Magge, R, DeAngelis, LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015; 29: 93–100.CrossRefGoogle ScholarPubMed
Park, SB, Goldstein, D, Krishnan, AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013; 63: 419–37.CrossRefGoogle ScholarPubMed
Vinblastine sulfate injection, solution package insert. Lake Zurich, IL: Fresenius Kabi USA, LLC; Jan 2017.Google Scholar
Vincristine sulfate injection, solution package insert. Lake Forest, IL: Hospira, Inc.; Jan 2017.Google Scholar
Vinorelbine injection, solution package insert. Parsippany, NJ: Actavis Pharma, Inc.; May 2015.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×